NEW DELHI (Pakistan Point News / Sputnik - 07th December, 2020) Indian biotechnology company Bharat Biotech has asked the Drugs Controller General of India (DCGI) for emergency use authorization of its coronavirus vaccine Covaxin, the Press Trust of India reported on Monday, citing sources.
Similar applications have already been filed with the Indian drugs watchdog by Pfizer/BioNTech for their BNT162b2 vaccine�and the Serum Institute of India for its Covishield, developed by the University of Oxford.
Covaxin is currently going through phase 3 clinical trials in India, involving 26,000 people.
In total, trials for eight COVID-19 candidate vaccines, including Russia's Sputnik V, are currently underway in India.
